CST, 57950S, CLEC12A/CLL-1 (E5T5V) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying CLEC12A. Validated for Western Blotting,Immunoprecipitation,Flow Cytometry (Live). Available in 2 sizes. Highly specific and rigorously validated in-house, CLEC12A/CLL-1 (E5T5V) Rabbit Monoclonal Antibody (CST #57950) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:100 Flow Cytometry (Live): 1:200 - 1:800 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody . Protocol Available protocols: Western Blotting, Immunoprecipitation, Flow Cytometry (Live) Specificity / Sensitivity CLEC12A/CLL-1 (E5T5V) Rabbit Monoclonal Antibody recognizes endogenous levels of total CLEC12A/CLL-1 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CLEC12A/CLL-1 protein. Background Part of the NK gene complex, C-type lectin-like molecule 1 (MICL/DCAL-2/CLL-1/CLEC12A) encodes a type-II transmembrane glycoprotein whose expression is largely restricted to hematopoietic cells of the myeloid lineage such as monocytes, macrophages, dendritic cells, and neutrophils (1-3). Research studies have shown that CLL-1 possesses a single C-type lectin-like domain within the extracellular domain and a single ITIM motif within its short cytoplasmic tail, which facilitates association with inhibitory SH2 domain-containing tyrosine phosphatases, SHP-1 and SHP-2. It is thought that signaling through the ITIM motif of CLL-1 facilitates inhibition of myeloid cell activation (1,2). By serving as a receptor for DAMPs that become exposed on dead cells, such as uric acid crystals, CLL-1 restrains pro-inflammatory immune responses that occur in response to cell death (4). In addition to being expressed on normal differentiated myeloid cells, research studies have also demonstrated expression of CLL-1 on the surface of malignant myeloid cells (5). As a result, CLL-1 has received significant attention as a potential novel therapeutic target for AML as its expression is absent from normal hematopoietic stem cells but is highly overexpressed on AML stem cells (5-9). Alternate Names C-type lectin domain family 12 member A; C-type lectin domain family 12, member A; C-type lectin protein CLL-1; C-type lectin superfamily; C-type lectin-like molecule 1; C-type lectin-like molecule-1; CD371; CL12A; CLEC12A; CLL-1; CLL1; DCAL-2; DCAL2; dendritic cell associated lectin 2; Dendritic cell-associated lectin 2; MGC70602; MICL; Myeloid inhibitory C-type lectin-like receptor Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 55-75 Source/Isotype: Rabbit IgG